Literature DB >> 4152167

Beta-adrenergic receptor blocking drugs in hypertension.

F O Simpson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4152167     DOI: 10.2165/00003495-197407010-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  81 in total

1.  Pindolol: a comparison with other antihypertensive drugs and a double-blind placebo trial.

Authors:  H J Waal-Manning; F O Simpson
Journal:  N Z Med J       Date:  1974-08-28

2.  Influence of an adrenergic beta-receptor blocking agent on the effect of various hypotensive agents in the hypertensive rat.

Authors:  H Brunner; P R Hedwall; M Meier
Journal:  Experientia       Date:  1965-04-15

3.  Propranolol as an antihypertensive agent.

Authors:  B N Prichard
Journal:  Am Heart J       Date:  1970-01       Impact factor: 4.749

4.  Adrenergic receptor mediation of renin secretion.

Authors:  N Winer; D S Chokshi; M S Yoon; A D Freedman
Journal:  J Clin Endocrinol Metab       Date:  1969-09       Impact factor: 5.958

5.  Pindolol, (Visken, LB46). A new treatment for hypertension: report of a multicentric open study.

Authors:  I S Collins; I W King
Journal:  Curr Ther Res Clin Exp       Date:  1972-04

6.  Effect of a selectivebeta-adrenergic blocker in preventing falls in arterial oxygen tension following isoprenaline in asthmatic subjects.

Authors:  K N Palmer; W F Hamilton; J S Lge; M L Diament
Journal:  Lancet       Date:  1969-11-22       Impact factor: 79.321

7.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

8.  Central hypotensive activity of dl- and d-propranolol.

Authors:  G J Kelliher; J P Buckley
Journal:  J Pharm Sci       Date:  1970-09       Impact factor: 3.534

9.  Practolol treatment in asthmatics.

Authors:  H J Waal-Manning; F O Simpson
Journal:  Lancet       Date:  1971-12-04       Impact factor: 79.321

10.  Propranolol in hypertension.

Authors:  B N Prichard; P M Gillam
Journal:  Am J Cardiol       Date:  1966-09       Impact factor: 2.778

View more
  38 in total

Review 1.  Hypertension: which beta-blocker?

Authors:  H J Waal-Manning
Journal:  Drugs       Date:  1976-12       Impact factor: 9.546

2.  Letter: Paradoxical effect of pindolol.

Authors:  H J Waal-Manning; F O Simpson
Journal:  Br Med J       Date:  1975-07-19

3.  Letter: Misleading drug advertising.

Authors:  B N Prichard
Journal:  Br Med J       Date:  1975-05-03

4.  Decrease in plasma noradrenaline levels following long-term treatment with prindolol in patients with essential hypertension.

Authors:  H M Brecht; F Banthien; W Schoeppe
Journal:  Klin Wochenschr       Date:  1976-11-15

5.  Problems with Beta Adrenergic Blocking Drugs and other Antihypertensive Drugs.

Authors:  B N Prichard
Journal:  Proc R Soc Med       Date:  1977

6.  Current status of Beta blocker therapy.

Authors:  J D Gray
Journal:  Can Fam Physician       Date:  1980-05       Impact factor: 3.275

7.  beta-Adrenoceptor blocking agents and human fat cell adenylate cyclase.

Authors:  H Kather; B Simon
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

8.  Penbutolol (Hoe 893d) in primary hypertension. Blood pressure effects, tolerance and plasma concentrations.

Authors:  K P Ohman; J Asplund; S Landahl; B Liander
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Dose-titrated, double-blind, cross-over comparison of a selective beta-blocker and methyldopa in the treatment of hypertension.

Authors:  P A Routledge; L V Zrinzo; J G Rao; R J Walden; D M Davies; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1977-03-11       Impact factor: 2.953

10.  Comparison of once and twice daily administration of sotalol in the treatment of hypertension.

Authors:  I Parvinen; E Paukkala
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.